GlassScriptPhysician profile
Rimma Pichkar
NPI 1174592836
$20,769.56
in general payments reported to CMS, 2019-2025
38 companies · $3,044 in 2025
The $3,044 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,489 · 2020: $2,028 · 2021: $3,411 · 2022: $3,793 · 2023: $3,095 · 2024: $2,909 · 2025: $3,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,048.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,229.96 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $3,533.36 | 2020-2025 | |
| Amgen INC. | $3,180.68 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,234.49 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $931.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $845.69 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $813.69 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $633.10 | 2021-2025 | |
| Genzyme Corporation | $624.49 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $480.06 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.96 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $382.62 | 2022-2024 | |
| Allergan, INC. | $377.85 | 2019-2020 | |
| Horizon Therapeutics Plc | $308.70 | 2020-2023 | Tepezza |
| Ironwood Pharmaceuticals, INC | $295.25 | 2021-2024 | Linzess |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rimma Pichkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.